Taro Pharmaceuticals Inc

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: $1.6B

Website

Clinical Trials

A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris

Early Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Tretinoin Cream 0.025%

First Posted Date: 2021-01-26

Last Posted Date: 2021-04-01

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1030

Registration Number: NCT04724473

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream

Phase 1

Completed

Conditions: Bioequivalence Study

Interventions: Drug: Clocortolone Pivalate

First Posted Date: 2020-04-24

Last Posted Date: 2020-04-24

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 124

Registration Number: NCT04358770

Locations: 🇺🇸
WayCro, Dallas, Texas, United States

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Clindamycin Phosphate
Drug: Clindamycin Phosphate RLD
Drug: Placebos

First Posted Date: 2020-03-25

Last Posted Date: 2020-03-25

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 550

Registration Number: NCT04321070

Locations: 🇺🇸
Catawba Research LLC, Charlotte, North Carolina, United States

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Placebo
Drug: CLPG Topical Gel 1%
Drug: Clindamycin

First Posted Date: 2019-10-22

Last Posted Date: 2019-10-22

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1260

Registration Number: NCT04134273

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

Phase 1

Completed

Conditions: Scalp Psoriasis

Interventions: Drug: Betamethasone Scalp Suspension 0.064%;0.0005%
Drug: Placebo topical suspension
Drug: Taclonex®

First Posted Date: 2019-03-19

Last Posted Date: 2019-03-19

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 485

Registration Number: NCT03880357

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

Phase 1

Completed

Conditions: Rosacea

Interventions: Drug: Finacea® (Azelaic acid Foam) 15%
Drug: Azelaic acid foam 15%
Drug: Vehicle of the test product

First Posted Date: 2018-09-28

Last Posted Date: 2019-03-19

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1116

Registration Number: NCT03689010

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

An Open-Label Study to Assess Safety

Phase 1

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Topical TA-102 A
Drug: Topical TA-102 B
Drug: Topical TA-102 C
Drug: Topical TA-102 D
Drug: Topical TA-102 E

First Posted Date: 2018-08-24

Last Posted Date: 2022-12-02

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 88

Registration Number: NCT03645499

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

Early Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Tretinoin cream, 0.05%
Drug: Vehicle of the test product
Drug: RETIN-A® (tretinoin) cream, 0.05%

First Posted Date: 2018-02-14

Last Posted Date: 2018-05-18

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 700

Registration Number: NCT03433378

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

Early Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: RETIN-A® Cream
Drug: Vehicle of the test product
Drug: Tretinoin cream 0.1%

First Posted Date: 2018-02-09

Last Posted Date: 2018-05-18

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 455

Registration Number: NCT03427554

Locations: 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States

A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%

Phase 1

Completed

Conditions: Lice; Head Lice

Interventions: Drug: Vehicle of the Test product
Drug: Ivermectin Lotion, 0.5%
Drug: SKLICE (ivermectin) Lotion, 0.5%

First Posted Date: 2017-08-22

Last Posted Date: 2018-05-18

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 413

Registration Number: NCT03257943

Locations: 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy